Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 689Other hematologic neoplasm 206Sarcoma 20Myeloid 18Plasma cell 12Dermatologic 6Classical hematology 6CNS 4Breast 2Thoracic 1Other solid neoplasm 1Other neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 547Pemetrexed 402Cisplatin 400Paclitaxel 272Docetaxel 255Gemcitabine 218pembrolizumab 190Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 179Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 106atezolizumab 92Gefitinib 74Radiosurgery 71anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 49Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Rituximab × Thoracic × Clear all
NCT00001805 2008-03-04

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
20 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡